Regnault A, Markowitz JT, Mazerolle F, Patel AM, Ciesluk A, Cano S, et al. A single metric for Pediatric and Adult versions of patient reported outcome measures: illustration in haemophilia. ISOQOL; 2019; San Diego, CA, USA.
Regnault A, Raimundo K, Patel AM, et al. Is the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) appropriate to measure the impact of hemophilia and its treatment? First quantitative survey. American Thrombosis and Hemostasis Network data summit; 2019; Chicago, IL, USA.
Regnault A, Raimundo K, Patel AM, Markowitz JT, Marquis P, Shapiro AD, et al. Is the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) appropriate to measure the impact of hemophilia and its treatment? First quantitative survey Hemostasis & Thrombosis Research Society; New Orleans, LA, USA, 2019.
Markowitz JT, Patel AM, Raimundo K, Marquis P, Shapiro AD, Konkle BA, et al. Early patient experiences with emicizumab in the United States: a qualitative study. International Society on Thrombosis and Haemostasis Congress; Melbourne, Australia, 2019.
Markowitz JT, Ma E, Solari PG, Marquis P, Shapiro AD, Konkle BA, et al. Development of a Concept-Driven Disease Impact Instrumentfrom Patients with Hemophilia (Pediatric and Adult) and Caregivers. American Thrombosis and Hemostasis Network Data Summit; Chicago, IL, USA, 2018.
Markowitz JT, Ma E, Solari PG, Marquis P, Shapiro AD, Konkle BA, et al. Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers. American Society of Hematology; Atlanta, GA, USA, 2017.
Carcao M, Kearney S, Santagostino E, Oyesiku JO, Young NL, Meunier J, et al. Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX. Haemophilia. 2017;23(3):e222-4.
Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;22(4):e267-74.
Seremetis S, Kulkarni R, Regnault A, Santagostino E. Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials. Clinical Investigation. 2015;5(9):755-66.
Ozelo M, Meunier J, Hoxer CS, Slothuus U. Quality of life and satisfaction of adults with haemophilia A switched to prophylactic treatment with recombinant factor VIII turoctocog alfa. EAHAD; Helsinki, Finland, 2015.
Ozelo M, Chowdary P, Regnault A, Busk AK. Impact of severe haemophilia A on patients' health status: results from the guardian™ 1 clinical trial of turoctocog alfa (NovoEight®). Haemophilia. 2015;21(4):451-7.
Chowdary P, Kearney S, Yee D, Meunier J, Slothuus U, Hoxer CS. Improved health status of haemophilia B patients treated with nonacog beta pegol, a new glycopegylated recombinant FIX product with prolonged half-life. ISPOR; Philadelphia, USA, 2015.
Chowdary P, Kearney S, Yee D, Meunier J, Slothuus U, Hoxer C. Improved health-related quality of life (HRQoL) of haemophilia B patients treated with a weekly 40IU/kg dose of a new long-acting recombinant factor IX (FIX) product, nonacog beta pegol. International Society of Thrombosis and Haemostasis (ISTH); 2015; Toronto, ON, Canada, 2015.
Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia. 2014;20(4):527-34.
Ozelo M, Chowdary P, Regnault A, Busk AK. Impact of severe haemophilia A on patients’ health status: results from the guardian™ 1 clinical trial of turoctocog alfa. World Federation of Hemophilia Congress; Melbourne, Australia, 2014.
Santagostino E, Lentz S, Iorio A, Busk A, Abad Franch L, Meunier J, et al. Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: Results from two clinical trials. 6th Annual Congress of the European Association for Haemophilia and Allied Disorders; Warsaw, Poland, 2013.